The abstract is read at the publisher; the summary is JClub's.
Intermittent anti-EGFR treatment in left-sided, non–microsatellite instability high RAS and BRAF V600E wild-type metastatic colorectal cancer shows consistently lower anti-EGFR skin toxicity than maintenance.
- Why it matters: Guidelines favor de-escalation after induction, but maintenance versus intermittent approaches were not directly compared for toxicity patterns over time in this specific patient subgroup.
- What they did: An individual patient data pooled analysis combined 3 randomized phase II trials (PanaMa, Valentino, PRODIGE-28 TIME), stratifying 327 patients into anti-EGFR plus 5-fluorouracil and leucovorin maintenance, anti-EGFR alone maintenance, or intermittent, then assessing toxicity over time longitudinally.
- The result: Mean anti-EGFR skin adverse event grades stayed lower with intermittent versus maintenance groups, and grades 3–4 were more represented in maintenance than intermittent, while grade 1 predominated across cycles for all groups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.